CD8A and neoplasm: While most preclinical studies in the literature are limited to CD8+ activation or tumor growth monitoring, this study comprehensively analyzed the immune response at both cellular and functional levels using ELISPOT, flow cytometry, and in vivo tumor volume measurements [38,45].